---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-041055"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2026-09-01T21:10:28+00:00"
generated_at: "2026-09-01T21:12:07.423410+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# INBS reports 98.2% accuracy in codeine drug screen study; 510(k) submission on track for Sept 2026

## Summary
- Multi-site study across 3 U.S. clinical sites: 98.2% accuracy, 94.6% sensitivity, 100% specificity for opiate codeine.
- Improvement from prior Nov 2024 study: ~94% accuracy and 82% sensitivity; specificity unchanged at 100%.
- Results measured against validated LC-MS/MS reference method; 70 true positives, 144 true negatives, 0 false positives.
- Company accelerated filing timeline; expects to submit 510(k) application in September 2026 for U.S. market entry.
- CEO Harry Simeonidis: 'we now have everything we need for our 510(k) submission.'

## SEC filing metadata
- accession: 0001493152-26-041055
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2026-09-01T21:10:28+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315226041055/0001493152-26-041055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315226041055/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-041055
- JSON: https://secwatch.observer/filing/0001493152-26-041055.json
- Plain text: https://secwatch.observer/filing/0001493152-26-041055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.